EZH2 Inhibitor Improves Cognitive Behavior in CAA

被引：0
|
作者：
Iqbal, Zahid
El Hamamy, Ahmad
Ngoc Mai Le
Ranjan, Arya
Qi, Li
Tan, Chunfeng
McCullough, Louise D.
Li, Jun
机构：
来源：
STROKE | 2024年 / 55卷
关键词：
D O I：
10.1161/str.55.suppl_1.WMP114
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
WMP114
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer
    Ma, Linlin
    Yan, Yuqian
    Bai, Yang
    Yang, Yinhui
    Pan, Yunqian
    Gang, Xiaokun
    Karnes, R. Jeffrey
    Zhang, Jun
    Lv, Qiubo
    Wu, Qiang
    Huang, Haojie
    THERANOSTICS, 2019, 9 (17): : 5020 - 5034
  • [42] New method for synthesis of EZH2 methyltransferase inhibitor GSK126
    Lu, Chen
    Zhang, Qiang
    Chen, Xin
    SYNTHETIC COMMUNICATIONS, 2016, 46 (14) : 1215 - 1222
  • [43] EZH2 PARlyation is involved in PARP inhibitor sensitivity in breast cancer cells
    Yamaguchi, Hirohito
    CANCER SCIENCE, 2018, 109 : 559 - 559
  • [44] Design and Characterization of a Pyridone-Containing EZH2 Inhibitor Phosphate Prodrug
    Kung, Pei-Pei
    Fan, Connie
    Gukasyan, Hovhannes J.
    Huang, Buwen
    Kephart, Susan
    Kraus, Manfred
    Lee, Joseph H.
    Sutton, Scott C.
    Yamazaki, Shinji
    Zehnder, Luke
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (03) : 1725 - 1732
  • [45] PRECLINICAL CHARACTERIZATION OF E7438, A POTENT, SELECTIVE EZH2 INHIBITOR WITH ROBUST ANTITUMOR ACTIVITY AGAINST EZH2 MUTATED NHL XENOGRAFTS IN MICE
    Keilhack, H.
    ANNALS OF ONCOLOGY, 2013, 24 : 13 - 13
  • [46] EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
    Beguelin, Wendy
    Popovic, Relja
    Teater, Matt
    Jiang, Yanwen
    Bunting, Karen L.
    Rosen, Monica
    Shen, Hao
    Yang, Shao Ning
    Wang, Ling
    Ezponda, Teresa
    Martinez-Garcia, Eva
    Zhang, Haikuo
    Zheng, Yupeng
    Verma, Sharad K.
    McCabe, Michael T.
    Ott, Heidi M.
    Van Aller, Glenn S.
    Kruger, Ryan G.
    Liu, Yan
    McHugh, Charles F.
    Scott, David W.
    Chung, Young Rock
    Kelleher, Neil
    Shaknovich, Rita
    Creasy, Caretha L.
    Gascoyne, Randy D.
    Wong, Kwok-Kin
    Cerchietti, Leandro
    Levine, Ross L.
    Abdel-Wahab, Omar
    Licht, Jonathan D.
    Elemento, Olivier
    Melnick, Ari M.
    CANCER CELL, 2013, 23 (05) : 677 - 692
  • [47] A study of combination therapy with histone methylase EZH2 inhibitor and PARP inhibitor in ovarian mucinous carcinoma
    Hachijo, Ryuta
    Sone, Kenbun
    Ishizaka, Aya
    Suzuki, Eri
    Hayashi, Minami
    Tanimoto, Saki
    Tsuchimochi, Saki
    Toyohara, Yusuke
    Fukuda, Tomohiko
    Taguchi, Ayumi
    Oda, Katsutoshi
    Osuga, Yutaka
    CANCER SCIENCE, 2024, 115 : 1403 - 1403
  • [48] Inhibition of the methyltranferase EZH2 improves aortic performance in experimental thoracic aortic aneurysm
    Cardenas, Christian L. Lino
    Kessinger, Chase W.
    MacDonald, Carolyn
    Jassar, Arminder S.
    Isselbacher, Eric M.
    Jaffer, Farouc A.
    Lindsay, Mark E.
    JCI INSIGHT, 2018, 3 (05):
  • [49] The role of EZH1 and EZH2 in development and cancer
    Lee, Soo Hyun
    Li, Yingying
    Kim, Hanbyeol
    Eum, Seounghyun
    Park, Kyumin
    Lee, Chul-Hwan
    BMB REPORTS, 2022, 55 (12) : 595 - 601
  • [50] Role of EZH2 in ovarian carcinogenesis
    Ali-Fehmi, R.
    Munkarah, A.
    Bryant, C. S.
    Shah, J. P.
    Kumar, S.
    Malone, J. M.
    Morris, R. T.
    Sood, A. K.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S150 - S150
12345